DE69629209D1 - Getrocknete zubereitung von bluttfaktoren, enthaltend trehalose - Google Patents

Getrocknete zubereitung von bluttfaktoren, enthaltend trehalose

Info

Publication number
DE69629209D1
DE69629209D1 DE69629209T DE69629209T DE69629209D1 DE 69629209 D1 DE69629209 D1 DE 69629209D1 DE 69629209 T DE69629209 T DE 69629209T DE 69629209 T DE69629209 T DE 69629209T DE 69629209 D1 DE69629209 D1 DE 69629209D1
Authority
DE
Germany
Prior art keywords
blood factor
preparation containing
dried blood
containing trehalose
factor preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69629209T
Other languages
English (en)
Other versions
DE69629209T2 (de
Inventor
Bruce Joseph Roser
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Quadrant Drug Delivery Ltd
Original Assignee
Elan Drug Delivery Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elan Drug Delivery Ltd filed Critical Elan Drug Delivery Ltd
Publication of DE69629209D1 publication Critical patent/DE69629209D1/de
Application granted granted Critical
Publication of DE69629209T2 publication Critical patent/DE69629209T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
DE69629209T 1995-01-19 1996-01-19 Getrocknete zubereitung von bluttfaktoren, enthaltend trehalose Expired - Lifetime DE69629209T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9501040 1995-01-19
GBGB9501040.1A GB9501040D0 (en) 1995-01-19 1995-01-19 Dried composition
PCT/GB1996/000119 WO1996022107A1 (en) 1995-01-19 1996-01-19 Dried blood factor composition comprising trehalose

Publications (2)

Publication Number Publication Date
DE69629209D1 true DE69629209D1 (de) 2003-08-28
DE69629209T2 DE69629209T2 (de) 2004-02-19

Family

ID=10768253

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69629209T Expired - Lifetime DE69629209T2 (de) 1995-01-19 1996-01-19 Getrocknete zubereitung von bluttfaktoren, enthaltend trehalose
DE69637749T Expired - Lifetime DE69637749D1 (de) 1995-01-19 1996-01-19 Getrocknete Blutfaktorzusammensetzung mit Trehalose

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE69637749T Expired - Lifetime DE69637749D1 (de) 1995-01-19 1996-01-19 Getrocknete Blutfaktorzusammensetzung mit Trehalose

Country Status (15)

Country Link
US (2) US6649386B2 (de)
EP (4) EP0871476B1 (de)
JP (1) JP3898221B2 (de)
KR (1) KR100417593B1 (de)
CN (1) CN1152713C (de)
AT (2) ATE413885T1 (de)
AU (1) AU704317B2 (de)
CA (2) CA2210872C (de)
DE (2) DE69629209T2 (de)
DK (2) DK1308170T3 (de)
ES (2) ES2316658T3 (de)
GB (1) GB9501040D0 (de)
PT (2) PT871476E (de)
SI (1) SI1308170T1 (de)
WO (1) WO1996022107A1 (de)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7253262B2 (en) * 1995-01-19 2007-08-07 Quandrant Drug Delivery Limited Dried blood factor composition comprising trehalose
GB9501040D0 (en) * 1995-01-19 1995-03-08 Quadrant Holdings Cambridge Dried composition
US7244824B2 (en) * 1995-01-19 2007-07-17 Quadrant Drug Delivery Limited Dried blood factor composition comprising trehalose
US6964771B1 (en) 1995-06-07 2005-11-15 Elan Drug Delivery Limited Method for stably incorporating substances within dry, foamed glass matrices
US6632648B1 (en) * 1996-05-14 2003-10-14 Elan Drug Delivery Limited Methods of terminal sterilization of fibrinogen
GB9616536D0 (en) 1996-08-06 1996-09-25 Quadrant Holdings Cambridge Co-amoxiclav dosage form
AUPO871997A0 (en) * 1997-08-25 1997-09-18 Csl Limited Dried biologically or therapeutically active preparations
CA2634663C (en) 1999-02-22 2009-08-25 University Of Connecticut Novel albumin-free factor viii formulations
BR0211842A (pt) * 2001-08-10 2004-08-31 Hayashibara Biochem Lab Associado, processos para produzir um associado de trealose ou maltitol e um ou mais compostos de ìon metálico, um produto em pó e um alimento marinho seco, método para formar um associado de trealose ou maltitol e um ou mais compostos de ìon metálico, composição, produto em pó, agente e tempero para alimentos
JP2007505147A (ja) 2003-09-12 2007-03-08 アンティジェニクス インコーポレーテッド 単純ヘルペスウイルス感染の治療および予防用ワクチン
WO2005094873A1 (en) * 2004-03-19 2005-10-13 Baxter International Inc. Factor ixa for the treatment of bleeding disorders
EP1758937B1 (de) 2004-05-24 2009-09-02 Genvault Corporation Stabile lagerung von protein und stabile lagerung von nukleinsäure in wiedergewinnbarer form
KR100624013B1 (ko) 2004-06-25 2006-09-19 주식회사 녹십자홀딩스 동결건조된 알부민 비함유 재조합 사람 혈액응고 제 8인자 제제
US8133484B2 (en) 2006-12-15 2012-03-13 Lifebond Ltd Hemostatic materials and dressing
CA2673260A1 (en) * 2006-12-20 2008-07-03 Bayer Healthcare Llc Factor vii and viia compositions
EP1958618A1 (de) * 2007-02-15 2008-08-20 Octapharma AG Verfahren zur Gefriertrocknung mit optimierter Rekonstitution von Biopolymeren
CA2991162A1 (en) * 2007-12-21 2009-07-02 Aptevo Biotherapeutics Llc Stabilized factor ix formulations containing trehalose
US11197916B2 (en) 2007-12-28 2021-12-14 Takeda Pharmaceutical Company Limited Lyophilized recombinant VWF formulations
TWI515006B (zh) * 2007-12-28 2016-01-01 巴克斯特國際公司 重組ｖｗｆ調配物
CN102177237B (zh) 2008-09-12 2013-10-30 金沃特公司 用于贮存和稳定生物分子的基质和介质
BRPI0919693A2 (pt) 2008-10-21 2020-08-11 Baxter Healthcare S.A formulação farmacêutica estável liofilizada
JP5779780B2 (ja) 2008-11-07 2015-09-16 バクスター・インターナショナル・インコーポレイテッドＢａｘｔｅｒ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｉｎｃｏｒｐ０Ｒａｔｅｄ 第ｖｉｉｉ因子製剤
BR112012015029A2 (pt) 2009-12-22 2017-06-27 Lifebond Ltd matriz reticulada, método para controlar a formação de uma matriz, método ou matriz, método para vedar um tecido contra vazamento de um fluído corporal, agente hemostático ou vedante cirúrgico, composição para vedar um ferimento, uso da composição, composição para um veículo para entrega localizada de fármaco, composição para engenharia de tecido, e método para modificar uma composição
EP2732262A4 (de) * 2011-07-13 2014-12-10 Denator Ab Verfahren zur stabilisierung von flüssigen biologischen proben
CN102416171B (zh) * 2011-12-06 2013-12-25 中国医学科学院输血研究所 高纯度凝血酶原复合物制品干热病毒灭活过程中的保护剂
US9700486B2 (en) 2013-04-24 2017-07-11 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
US20160317646A1 (en) * 2013-12-19 2016-11-03 Crucell Holland B.V. Formulations for virosomes
MX2017000862A (es) 2014-08-04 2017-05-01 Csl Ltd Formulacion de factor viii.
EA201792501A1 (ru) 2015-05-13 2018-10-31 Эйдженус Инк. Вакцины для лечения и профилактики рака
CN107333750A (zh) * 2017-06-11 2017-11-10 成都吱吖科技有限公司 一种长时血液细胞稳定剂
JP2021522239A (ja) 2018-04-26 2021-08-30 アジェナス インコーポレイテッド 熱ショックタンパク質結合ペプチド組成物およびその使用方法
WO2021001522A1 (en) 2019-07-04 2021-01-07 CSL Behring Lengnau AG A truncated von willebrand factor (vwf) for increasing the in vitro stability of coagulation factor viii
EP4240757A2 (de) 2020-11-09 2023-09-13 Takeda Pharmaceutical Company Limited Reinigung von fviii aus plasma mittels siliciumoxidadsorption
WO2022261716A1 (en) * 2021-06-16 2022-12-22 Exopharm Limited Aqueous formulations for preservation of extracellular vesicles

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4361509A (en) 1981-12-14 1982-11-30 Scripps Clinic And Research Foundation Ultrapurification of factor VIII using monoclonal antibodies
US4495175A (en) * 1982-08-05 1985-01-22 University Of Rochester Preparation of highly purified human antihemophilic factor
FI86885C (fi) 1984-04-20 1992-10-26 Genentech Inc Foerfarande foer framstaellning av human rekombinantfaktor viii och nukleinsyrasekvenser och vektorer anvaend daertill
EP0182448A3 (de) 1984-08-24 1987-10-28 Genetics Institute, Inc. Verfahren zur Herstellung von Faktor VIII und verwandte Produkte
DE3682047D1 (de) * 1985-07-09 1991-11-21 Quadrant Bioresources Ltd Beschuetzung von proteinen und aehnlichem.
US4758657A (en) * 1985-07-11 1988-07-19 Armour Pharmaceutical Company Method of purifying Factor VIII:C
US4806343A (en) * 1986-03-13 1989-02-21 University Of Southwestern Louisiana Cryogenic protectant for proteins
CA1329760C (en) * 1987-10-29 1994-05-24 Ted C. K. Lee Plasma and recombinant protein formulations in high ionic strength media
US4877608A (en) * 1987-11-09 1989-10-31 Rorer Pharmaceutical Corporation Pharmaceutical plasma protein formulations in low ionic strength media
CA2051092C (en) * 1990-09-12 2002-07-23 Stephen A. Livesey Method and apparatus for cryopreparation, dry stabilization and rehydration of biological suspensions
DE4111393A1 (de) 1991-04-09 1992-10-15 Behringwerke Ag Stabilisierte faktor viii-praeparationen
US5288853A (en) 1992-04-30 1994-02-22 Alpha Therapeutic Corporation Factor viii purification process
WO1994007510A1 (en) * 1992-10-02 1994-04-14 Kabi Pharmacia Ab Composition comprising coagulation factor viii formulation, process for its preparation and use of a surfactant as stabilizer
SE504074C2 (sv) * 1993-07-05 1996-11-04 Pharmacia Ab Proteinberedning för subkutan, intramuskulär eller intradermal administrering
WO1995003332A1 (en) 1993-07-23 1995-02-02 Baxter International Inc. Activated human factor viii and method of preparation
US5576291A (en) * 1993-09-13 1996-11-19 Baxter International Inc. Activated factor VIII as a therapeutic agent and method of treating factor VIII deficiency
US5955448A (en) 1994-08-19 1999-09-21 Quadrant Holdings Cambridge Limited Method for stabilization of biological substances during drying and subsequent storage and compositions thereof
US7253262B2 (en) * 1995-01-19 2007-08-07 Quandrant Drug Delivery Limited Dried blood factor composition comprising trehalose
GB9501040D0 (en) * 1995-01-19 1995-03-08 Quadrant Holdings Cambridge Dried composition
US5804420A (en) * 1997-04-18 1998-09-08 Bayer Corporation Preparation of recombinant Factor VIII in a protein free medium
CA2634663C (en) 1999-02-22 2009-08-25 University Of Connecticut Novel albumin-free factor viii formulations

Also Published As

Publication number Publication date
DK0871476T3 (da) 2003-11-10
EP2258402A2 (de) 2010-12-08
CN1152713C (zh) 2004-06-09
CA2671383A1 (en) 1996-07-25
US6649386B2 (en) 2003-11-18
CA2210872A1 (en) 1996-07-25
EP1308170A3 (de) 2004-03-03
KR100417593B1 (ko) 2004-04-30
SI1308170T1 (sl) 2009-04-30
CA2210872C (en) 2009-09-08
WO1996022107A1 (en) 1996-07-25
GB9501040D0 (en) 1995-03-08
EP1974741A1 (de) 2008-10-01
JP3898221B2 (ja) 2007-03-28
CA2671383C (en) 2012-04-24
JPH11503719A (ja) 1999-03-30
PT1308170E (pt) 2008-12-26
EP2258402A3 (de) 2011-01-05
ATE245442T1 (de) 2003-08-15
CN1179107A (zh) 1998-04-15
AU704317B2 (en) 1999-04-22
ES2316658T3 (es) 2009-04-16
KR19980701500A (ko) 1998-05-15
PT871476E (pt) 2003-12-31
ES2202425T3 (es) 2004-04-01
EP0871476A1 (de) 1998-10-21
ATE413885T1 (de) 2008-11-15
DE69637749D1 (de) 2008-12-24
US20090149388A1 (en) 2009-06-11
US20020128207A1 (en) 2002-09-12
EP0871476B1 (de) 2003-07-23
US7803911B2 (en) 2010-09-28
EP1308170A2 (de) 2003-05-07
DK1308170T3 (da) 2008-12-15
AU4454096A (en) 1996-08-07
EP1308170B1 (de) 2008-11-12
DE69629209T2 (de) 2004-02-19

Similar Documents

Publication Publication Date Title
DE69629209D1 (de) Getrocknete zubereitung von bluttfaktoren, enthaltend trehalose
MX9304710A (es) Composicion farmaceutica y/o cosmetica y su uso.
NO179911C (no) Optisk aktivt 5H-pyrrolo[3,4-bÅpyrazinderivat samt farmasöytiske preparater inneholdende derivatet
ATE105297T1 (de) Derivate von 2'-halomethyliden, 2'-ethenyliden und 2'-ethynylcytidin, uridin und guanosin.
MX9203459A (es) Nuevos derivados de 2'-halometilideno, 2'-etenilideno y 2'-etinilcitidina, uridina y guanosina.
ATE92542T1 (de) Azeotropaehnliche zusammensetzungen von 1,1dichlor-2,2,2-trifluoraethan und 1,1-dochlor-1fluor|than.
DE3576505D1 (de) 3,4-dihydrobenzopyranverbindungen und diese enthaltende pharmazeutische zusammenstellungen.
DK0453603T3 (da) Piroxicamholdige farmaceutiske præparater til topisk anvendelse
DE59208622D1 (de) Dentalwerkstoffe auf Basis von (Meth)-Acrylaten
DK0437225T3 (da) Topiske præparater
DE69208681D1 (de) Verwendungen von 1,1,1,3,3,3-hexafluoropropan
FI923751A (fi) Hexahydrobenso/f/kinolinoner
ATE132877T1 (de) Emulgatorfreie emulsionspolymere in pharmazeutischen zubereitungen mit verzögerter wirkstofffreigabe und ihre herstellung
DE68907609D1 (de) Arzneimittelzusammensetzung.
DE69001580D1 (de) Perkutane verabreichung von 3'-azido-3'-deoxythymidin.
DE3889336T2 (de) Alkyltetramethylcyclohexan-derivate und deren verwendung als duftstoffe.
KR900700471A (ko) 신규의 2,3-티오모르폴린디온-2-옥심유도체, 이들을 함유하는 약제학적 조성물 및 제법
DE3869232D1 (de) Abkoemmlinge von bornan-3-spiro-l'-cyclopentan und diese enthaltende riechstoffzusammensetzungen.
IT1215261B (it) Composizioni farmaceutiche adattivita' antigalattopoietica.
MX9203261A (es) Nuevas 12-amino-piridazino [4',5':3,4] pirrolo[2,1-a]-isoquinolinas y composiciones farmaceuticas que las contienen.
ATE82138T1 (de) Geregelte verabreichungszusammensetzung.
DE68916472T2 (de) Polyäthylen-Zusammensetzung.
ES1012015Y (es) Calzado infantil perfeccionado.
IT1207432B (it) Dispositivi per la chiusura rapida di calzature per attivita'sciatorie, coordinati per la tenuta differenziabile e l'articolazione controllata degli arti calzati.
IT8559352V0 (it) Dispositivi per la chiusura rapida di calzature per attivita'sciatorie, coordinati per la tenuta differenziabile e l'articolazione controllata degli arti calzati.

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: QUADRANT DRUG DELIVERY LTD., RUDDINGTON, NOTTINGHA

8364 No opposition during term of opposition